Intuitive Surgical is the closest thing the health care industry has to Google Inc. With shares trading at or around $300 at publishing time, the robotic surgery pioneer clearly leads the field in a review of five-year and one-year stock valuations of publicly-traded medical device companies conducted by IN VIVO. According to this survey, over the past five years, public investors have shown a strong level of support for the stock of companies with a laser-like focus on a single market area.
Intuitive Surgical Inc. is the closest thing the health care industry has to Google Inc. With shares trading at or around $300 at publishing time, the robotic surgery pioneer clearly leads the field in a review of five-year and one-year stock valuations of publicly-traded medical device companies conducted by IN VIVO.
According to this survey, over the past five years, public investors have shown a strong level of support for the...
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
